For employers

When the medication stops,performance is on the line.

Women aged 45 to 55 are your most experienced leaders and your succession pipeline. They are also the group most likely to be using GLP-1 medication, and the group navigating menopause. Food noise, low energy and lost confidence don’t stay at home. They show up in focus, decisions and the promotions women stop going for.

A woman working at a laptop at her kitchen table by a window

The opportunity

The opportunity your organisation is missing.

GLP-1 medication is changing the lives of thousands of women in your workforce. It quiets hunger, reduces food noise, and in many cases transforms how women feel at work.

But most organisations are not thinking about what happens when it stops.

When women taper or come off GLP-1 medication without support, appetite returns, food noise returns, and the confidence and clarity gains they made during treatment are at risk. The investment the medication represented, in time, in cost, in the woman’s own wellbeing, can unravel quickly without the right support in place.

The Food Noise Doctor community exists to make sure that doesn’t happen.

The performance case.

£31billion a year

The UK productivity cost of obesity and excess weight, including £9.7 billion from reduced focus and energy at work and £8.3 billion in sick days.

Source: Nesta and Frontier Economics, 2025.

17.3%fewer long-term sick days

Long-term sick leave fell by 17.3% after people started GLP-1 treatment. Employers risk losing that gain when treatment stops without support.

Source: NBER Working Paper 35475, 2026.

44%of menopausal women aged 45 to 55

Said their ability to work had been affected by menopause symptoms.

Source: Fawcett Society, Menopause and the Workplace, 2022.

61%lost motivation. 52% lost confidence.

Because of menopause symptoms, in the same age group most likely to be on GLP-1 medication.

Source: Fawcett Society, 2022.

8%did not apply for promotion. 1 in 10 left their job.

Because of menopause symptoms. These are your most experienced women.

Source: Fawcett Society, 2022.

£1.7billion a year

Estimated cost of menopause to the UK economy in sick days, lost productivity and women leaving work.

Source: Mariella Frostrup, UK Government Menopause Employment Ambassador, 2026.

25%faster decline in executive function

In adults getting over 20% of their calories from ultra-processed foods. Average age 51. Planning, decision making, and leadership capacity are directly affected by what your team eats.

Source: University of São Paulo, 10,000+ adults, reported 2022. Linked to, not proven cause.

Lowerattention scores

Each 10% rise in ultra-processed food intake was linked to lower attention scores in adults aged 40 to 70.

Source: Monash University, 2026. Linked to, not proven cause.

1 in 10workers

Would tell a new employer they use GLP-1 medication. 32% have kept weight loss efforts private at work. Your employees are navigating this without you knowing.

Source: ZipHealth survey, 2026.

Private by design

Private by design.

1 in 10

of workers would disclose their medication to a new employer.

Nearly 1 in 3

have kept their weight loss efforts entirely private at work.

Your employees are not going to tell you they’re on GLP-1 medication. The data confirms it. Only 1 in 10 workers would disclose their medication to a new employer, and nearly a third have kept their weight loss efforts entirely private at work.

That’s not a trust problem. It’s a privacy instinct, and it’s completely understandable.

What it means for you as an employer is that the women in your organisation who are navigating medicated weight loss, the tapering process, the return of food noise, and the identity shifts that come with all of it, are doing so invisibly. They are sitting in your meetings, leading your teams, and managing their own transitions without telling anyone.

The Food Noise Doctor community is built for exactly this. It’s private, it’s self-directed, and it doesn’t require a woman to disclose anything to her employer, her manager, or her colleagues. She accesses it on her own terms, in her own time, with the support she actually needs.

What you provide is the access. What she does with it is entirely hers.

The menopause connection

The women most likely to be on GLP-1 medication are the same women navigating menopause.

The same women moving into leadership. The same women your succession planning depends on.

UK employers with 250 or more staff are being asked to publish menopause action plans. A programme that supports midlife women through food noise, identity shifts, and the transition off GLP-1 medication sits squarely within that commitment.

This is not a wellness perk. It’s a retention and performance strategy for the women your organisation cannot afford to lose.

What we offer employers

A private, self-directed support programme that your employees access on their own terms.

Just the support your most experienced women need to maintain the gains the medication gave them, long after the prescription ends.

Get in touch to discuss a corporate partnership

Corporate partnerships

Let’s talk about
your team.

Tell us a little about your organisation and we’ll be in touch to discuss a corporate partnership.

Prefer email? Write to hello@thefoodnoisedoctor.com with “Corporate” in the subject line.

About you.
Your organisation.

We’ll only use these details to reply to your enquiry. See our Privacy Policy.

About these figures

The statistics on this page are sourced from published research and reports. Ultra-processed food figures reflect associations identified in observational studies and do not establish cause. Links to primary sources are provided where available. Speak to a qualified professional about the specific needs of your organisation and workforce.